Insight from Lymphocyte-Albumin Scores into Treatment Continuity of Nanoliposomal Irinotecan With 5-Fluorouracil and L-leucovorin in Metastatic Pancreatic Cancer
In Vivo · 2024
DOI: 10.21873/invivo.13768 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Vivo, 2024. Verfasst von Takahiro Ito und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Wakayama Medical University, Wakayama, Japan. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Fluorouracil, Leucovorin, Irinotecan. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND/AIM: Nanoliposomal irinotecan with 5-fluorouracil and L-leucovorin (nal-IRI/FL) is the standard regimen for metastatic pancreatic cancer, but there are no reports on prediction of early discontinuation. In this study, we investigated predictive factors of early discontinuation of nal-IRI/FL. PATIENTS AND METHODS: The study included 36 patients who received nal-IRI/FL at Wakayama Medical University Hospital between June 2021 and May 2022. Those with time-to-treatment failure (TTF) ≤28 days were defined as the early discontinuation group (group ED), and those with TTF >28 days were placed in the continuation group (group C). Laboratory data were collected just before and every 14 days after initiation of nal-IRI/FL treatment. RESULTS: There were six patients (16.7%) in group ED and 30 patients (83.3%) in group C. The lymphocyte×albumin (LA) score before therapy was significantly lower in group ED (p=0.005). In receiver operating characteristic analysis, pre-treatment LA was the best predictor for early discontinuation, with a cutoff value of 4,142 (sensitivity: 1.00, specificity: 0.77, p=0.004). In group C, LA was significantly lower at 28 days before nal-IRI/FL treatment failure compared to the value before the start of therapy [median with range: 3,299 (1,478-6,994) vs. 4,304 (2,085-8,085), p=0.006]. CONCLUSION: The LA score is a useful marker for evaluating treatment continuity, and especially early discontinuation, of nal-IRI/FL in patients with pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Wakayama Medical University, Wakayama, Japan.
- School of Pharmaceutical Sciences, Wakayama Medical University, Wakayama, Japan; sunoma@wakayama-med.ac.jp.
- Second Department of Internal Medicine, School of Medicine, Wakayama Medical University, Wakayama, Japan.
- Second Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama, Japan.
- Department of Pharmacy, Wakayama Medical University Hospital, Wakayama, Japan.
Zitieren
APA
Ito, T., Suno, M., Shintani, M., Iwata, A., Ashida, R., Kawai, M., & Matsubara, K. (2024). Insight from Lymphocyte-Albumin Scores into Treatment Continuity of Nanoliposomal Irinotecan With 5-Fluorouracil and L-leucovorin in Metastatic Pancreatic Cancer. In Vivo. https://doi.org/10.21873/invivo.13768
Vancouver
Ito T, Suno M, Shintani M, Iwata A, Ashida R, Kawai M, et al. Insight from Lymphocyte-Albumin Scores into Treatment Continuity of Nanoliposomal Irinotecan With 5-Fluorouracil and L-leucovorin in Metastatic Pancreatic Cancer. In Vivo. 2024. doi:10.21873/invivo.13768
BibTeX
@article{Ito2024,
author = {Ito, Takahiro and Suno, Manabu and Shintani, Minae and Iwata, Ayaka and Ashida, Reiko and Kawai, Manabu and Matsubara, Kazuo},
title = {Insight from Lymphocyte-Albumin Scores into Treatment Continuity of Nanoliposomal Irinotecan With 5-Fluorouracil and L-leucovorin in Metastatic Pancreatic Cancer},
journal = {In Vivo},
year = {2024},
doi = {10.21873/invivo.13768}
}
EUVIMED